Charcot neuro-osteoarthropathy

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 1, 2008, Pages

  Jeffcoate, William J ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Charcot neuro osteoarthropathy; Diabetic foot; Osteoprotegerin; Pro inflammatory cytokines; RANKL

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CYTOKINE; DENOSUMAB; ETANERCEPT; GLUCOCORTICOID; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LEPTIN; METHYLPREDNISOLONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SEX HORMONE; TUMOR NECROSIS FACTOR ALPHA;

AGE; BONE INJURY; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL FEATURE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; FOOT FRACTURE; FOOT MALFORMATION; FOOT ULCER; FRAGILITY FRACTURE; HUMAN; INFLAMMATION; MORBIDITY; NEUROPATHIC JOINT DISEASE; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHROPATHY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ARTHROPATHY, NEUROGENIC; BONE DISEASES, METABOLIC; DISEASE PROGRESSION; HUMANS; INFLAMMATION;

EID: 44949083702     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.837     Document Type: Conference Paper

References (33)

1. Mitchell JK. On a new practice in acute and chronic rheumatism. Am J Med Sci 1831; 8: 55-64.
2. Charcot JM. Sur quelques arthropathies qui paraiise dépendre d'une lésion du cerveau ou de la mouelle épinièe. Arch Physiol Norm Pathol 1868; 1: 161-178.
3. Charcot JM, Féré C. Affections ossueses ot articulaires du pied chez les tabétiques. Bull Soc Anatomique Paris 1883; 8: 324-327.
4. Sanders I.J. The Charcot foot: historical perspective 1827-2003. Diabetes Metab Res Rev 2004; 20(Suppl. 1): S4-S8.
5. Jordan WR. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936; 57: 307-366.
6. Saunders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. In Levin and ONeal's The Diabetic Foot (6th edn), Bowker JH, Pfeifer MA (eds). Mosby: St Louis, MO, 2001; 439-466.
7. Jeffcoate WJ, Lima J, Nóbrega L. The Charcot foot. Diabet Med 2000; 17: 253-258.
8. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-1096.
9. Hartemann-Heurtier A, Ha Van G, Grimaldi A. The Charcot foot. Lancet 2002; 360: 1776-1779.
10. Game F, Catlow R, Jeffcoate W, et al. CDUK: a UK-wide, webbased survey of the management of the acute Charcot foot of diabetes. Diabetologia 2007; 50(Suppl. 1): P1116.
11. Sinha S, Munichoodappa C, Kozak GP. Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972; 51: 191-210.
12. Clouse ME, Gramm HF, Legg M, Flood T. Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. Am J Roentgenol Radium Ther Nucl Med 1974; 121: 22-33.
13. Larsen K, Fabrin J, Holstein PE. Incidence and management of ulcers in diabetic Charcot feet. J Wound Care 2001; 10: 323-328.
14. Ziegler R. Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 1992; 26: 90-94.
15. Cundy T, Edmonds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985; 2: 461-464.
16. Kayath MJ, Dib SA, Viela JG. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complicat 1994; 8: 97-104.
17. Forst T, Pfutzner A, Kann P, et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 874-879.
18. Rix M, Andreasson H, Eskilden P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999; 22: 827-831.
19. Khosla S. Minireview: the OPG/RANK: system. Endocrinology 2001; 142: 5050-5055.
20. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001; 358: 257-259.
21. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323-6331.
22. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1157.
23. Whitehouse FW, Weckstein M. On diabetic osteopathy: a radiographic study of 21 patients. Diabetes Care 1978; 1: 303-304.
24. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. Br Med J 1982; 284: 928-930.
25. Lithner F, Hietala SO, Steen L. Skeletal lesions and arterial calcifications of the feet in diabeties. Acta Med Scand Suppl 1984; 687: 47-54.
26. Gentile S, Bizarro A, Marmo R, de Bellis A, Orlando C. Medial arterial calcification and diabetic neuropathy. Acta Diabetol Lat 1990; 27: 243-253.
27. Psyrogiannis A, Kyriazooulou V, Vagenakis AG. Medial arterial calcification is frequently found in patients with microalbuminuria. Angiology 1999; 50: 971-975.
28. Jeffcoate WJ, Game FL, Cavanagh PR. the role of proinflammatory cytokines in the cayuse of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366: 2058-2061.
29. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 2006; 26: 6453-6468.
30. Shapiro SA, Stansberry KB, Hill MA, et al. Normal blood flow response and vasomotion in the diabetic Charcot foot. J Diabetes Complicat 1998; 12: 147-153.
31. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457-463.
32. Baker N, Green A, Krishnan S, Rayman G. Microvascular and C-fibre function in diabetic Charcot neuro-arthropathy and diabetic peripheral neuropathy. Diabetes Care 2007; 30: 3077-3079.
33. Jeffcoate WJ. Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy. Curr Diab Rep 2005; 5: 430-435.